Contribution: Industrial Research Assistance Program – Contributions to Firms
Entos Pharmaceuticals Inc.
$250,000.00
In Vivo Validation of Fusogenix Formulations Optimized for Delivery of Genetic Medicines to the Trabecular Meshwork of the Eye
EF 2025-26 · 2025-04-01
Résumé
In partnership with a large Multinational Pharmaceutical Partner, the Firm will evaluate the safety and effectiveness of its Fusogenix formulations optimized for delivery of genetic medicines to the trabecular meshwork of the eye to treat ophthalmological diseases. The project will validate previously optimized trabecular meshwork formulations combined with the pharma partners mRNA cargo and Entos cargoes including DNA in small and large animal models.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Edmonton|Edmonton, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
816561112
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2026-03-31
Agreement Number
1029894
Agreement Start Date
2025-04-01
Agreement Title
In Vivo Validation of Fusogenix Formulations Optimized for Delivery of Genetic Medicines to the Trabecular Meshwork of the Eye
Agreement Title (French)
Validation in vivo de formulations de Fusogenix optimisées pour l’administration de médicaments génétiques au réseau trabéculaire de l’œil
Agreement Type
Contribution
Agreement Value
$250,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
In partnership with a large Multinational Pharmaceutical Partner, the Firm will evaluate the safety and effectiveness of its Fusogenix formulations optimized for delivery of genetic medicines to the trabecular meshwork of the eye to treat ophthalmological diseases. The project will validate previously optimized trabecular meshwork formulations combined with the pharma partners mRNA cargo and Entos cargoes including DNA in small and large animal models.
Description (French)
En partenariat avec une grande multinationale pharmaceutique, l’entreprise évaluera la sécurité et l’efficacité de ses formulations de Fusogenix optimisées pour l’administration de médicaments génétiques au réseau trabéculaire de l’œil afin de traiter des maladies ophtalmologiques. Le projet validera des formulations précédemment optimisées pour le réseau trabéculaire, combinées à des cargaisons d’ARNm et d’Entos, y compris de l’ADN, chez des modèles animaux de petite et grande taille.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
816561112
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Entos Pharmaceuticals Inc.
Recipient Postal Code
T5J 4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2025-2026-Q1-1029894
